Valuation : CSL Limited

Market Cap 60.46B 51.98B 48.9B 44.63B 83.28B 5,731B 83.71B 579B 224B 2,930B 227B 222B 9,322B P/E 2027 *
20.7x
P/E 2028 * 18.8x
Enterprise Value 69.39B 59.66B 56.13B 51.22B 95.59B 6,578B 96.08B 665B 257B 3,362B 261B 255B 10,699B EV / Sales 2027 *
4.4x
EV / Sales 2028 * 4.23x
Free-Float
99.97%
Yield 2027 *
2.38%
Yield 2028 * 2.52%
1 day-0.78%
1 week-1.52%
Current month-0.21%
1 month+27.32%
3 months+72.12%
6 months+20.38%
Current year-0.83%
1 week 170.01
Extreme 170.01
177.39
1 month 131.85
Extreme 131.85
177.39
Current year 90
Extreme 90
184.62
1 year 90
Extreme 90
222.47
3 years 90
Extreme 90
313.55
5 years 90
Extreme 90
319.78
10 years 90
Extreme 90
342.75
Manager TitleAgeSince
Chief Executive Officer 63 2026-02-10
Director of Finance/CFO 52 2025-10-06
Chief Operating Officer - 2025-04-30
Director TitleAgeSince
Director/Board Member 72 2018-10-16
Director/Board Member 70 2011-02-01
Director/Board Member 71 2019-12-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/26/26 Free

Director

523 0.0001%
8/26/26 Free 317 0.0001% -
8/26/26 Free

Director

1,586 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.78%-1.52%-18.45%-36.25% 60.46B
-2.10%-1.64%+45.10%-2.45% 80.91B
-3.59%-9.04%+465.16%+30.37% 56.02B
-1.77%-5.26%-9.16%+29.36% 49.63B
-0.87%-6.98%-1.91%+148.85% 45.88B
-3.77%-1.64%+50.34%-17.95% 31.4B
-1.85%-0.49%+43.72%+94.44% 25.22B
-2.10%-3.54%-2.68%+156.40% 22.25B
-0.77%-0.09%+65.58%+110.60% 16.59B
-3.15%-7.97%-24.67%+719.34% 14.38B
Average -2.06%-2.11%+61.30%+123.27% 40.27B
Weighted average by Cap. -2.02%-1.64%+77.99%+62.25%

Financials

2027 *2028 *
Net sales 15.76B 13.55B 12.75B 11.64B 21.71B 1,494B 21.83B 151B 58.45B 764B 59.19B 57.9B 2,431B 16.31B 14.02B 13.19B 12.04B 22.47B 1,546B 22.59B 156B 60.48B 790B 61.25B 59.91B 2,515B
Net income 2.84B 2.44B 2.3B 2.09B 3.91B 269B 3.93B 27.19B 10.52B 137B 10.65B 10.42B 438B 3.17B 2.72B 2.56B 2.34B 4.36B 300B 4.38B 30.34B 11.74B 153B 11.89B 11.63B 488B
Net Debt 8.93B 7.68B 7.22B 6.59B 12.3B 847B 12.37B 85.59B 33.11B 433B 33.54B 32.8B 1,377B 8.46B 7.28B 6.85B 6.25B 11.66B 802B 11.72B 81.11B 31.38B 410B 31.78B 31.08B 1,305B
Logo CSL Limited
CSL Limited is an Australia-based biotechnology company. The Company’s areas of focus include rare and serious diseases, influenza vaccines and iron deficiency and nephrology. The Company’s segments include CSL Behring, CSL Seqirus and CSL Vifor. The CSL Behring segment manufactures, markets and distributes plasma products, gene therapies and recombinants. The CSL Seqirus segment manufactures, markets and distributes predominantly influenza related products and provides pandemic services to governments. The CSL Vifor segment manufactures, markets and distributes products in the therapeutic areas of iron deficiency and nephrology. Its CSL Plasma operates plasma collection networks, with approximately 325 plasma collection centers in the United States, Europe and China. The Company operates in Australia, the United States, Germany, the United Kingdom, Switzerland and China (including Hong Kong). Its products include Respreeza, Zemaira, HAEGARDA, KCENTRA, Hepatitis B, Evogam, and others.
Employees
29,000
Date Price Change Volume
26-09-09 A$171.21 -0.78% 1,248,921
26-09-08 A$174.80 +0.94% 954,984
26-09-07 A$173.18 -0.76% 721,894
26-09-04 A$174.50 -0.57% 1,074,568
26-09-03 A$175.50 +0.95% 1,150,239
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
126.24USD
Average target price
123.18USD
Spread / Average Target
-2.42%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!